G9A AND GLP METHYLATE LYSINE 373 IN THE TUMOR SUPPRESSOR P53

Jing Huang, Jean Dorsey, Sergei Chuikov, Xinyue Zhang Thomas Jenuwein, Danny Reinberg, and Shelley L. Berger

Supplementary Experimental Procedures

siRNA sequences:

G9a_siRNA#1: sense, UGAGAGAGGAUGAUUCUUAUU; anti-sense, 5'-PUAAGAAUCAUCCUCUCUCAUU

G9a_siRNA#2: sense, GAACAUCGAUCGCAACAUCUU; anti-sense, 5'-PGAUGUUGCGAUCGAUGUUCUU

Glp_siRNA#1: sense, CAAACAGCGUGGUCAAGUAUU; anti-sense, 5'-PUACUUGACCACGCUGUUUGUU

Glp_siRNA#2: sense, CAAGAAAGGCCACUACGAAUU; anti-sense, 5'-PUUCGUAGUGGCCUUUCUUGUU

Realtime PCR primer sequences:

G9a mRNA: forward, 5'-TCATGCTGCACCAAGACCTG-3'; reverse, 5'-GGGAACTGAAGAAGGCGATG-3'

Glp mRNA: forward, 5'-TCCAAGGCCAAAGAGGTGAC-3'; reverse, 5'-CACGGTCGAGGTGGTGTCT-3'

GAPDH mRNA: forward, 5'-TGGGCTACACTGAGCACCAG-3'; reverse, 5'-GGGTGTCGCTGTTGAAGTCA-3'



Figure S1. Dotblot analysis to characterize the p53K373me2 antibody. Serial dilution of p53 peptides (as indicated) are dotted on the PVDF membrane followed by blotting with 1:1,000 dilution of p53K373me2 antibody.



Figure S2. Realtime PCR analysis to assess the knockdown efficiency of siRNAs for luciferase (Luc_si), G9a (G9a_si#1 or #2), Glp (Glp_si#1 or #2) and both (G9a+Glp_si). Shown are normalized values of G9a or Glp mRNA levels to those of GAPDH (internal controls). The normalized value for Luci_si without adriamycin treatment was set as 1. Shown are the relative mRNA level from the averages of two independent repeats.